Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
0.3326
+0.0576 (20.95%)
At close: May 6, 2026, 4:00 PM EDT
0.313827
-0.0188 (-5.64%)
After-hours: May 6, 2026, 5:42 PM EDT
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.
The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023.
The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Medicus Pharma Ltd.
| Country | United States |
| Founded | 2008 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Raza Bokhari |
Contact Details
Address: 300 Conshohocken State Road, Suite 200 West Conshohocken, Pennsylvania 19428 United States | |
| Phone | 610 636 0184 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raza Bokhari M.B.A., M.D. | Chief Executive Officer and Executive Chairman |
| Dr. Edward J. Brennan Jr., F.A.C.S., M.D. | Chief Scientific Officer and Head of Research & Development Program |
| Andrew Alasdair Smith | Chief Operating Officer |
| Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
| Viktoria Slepeniuk | Senior Vice President of Public Relations |
| Dr. Faisal Mehmud M.D. | Chief Medical Officer |
| Maryann Adesso | Chief of Staff and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2026 | SCHEDULE 13G/A | Filing |
| May 4, 2026 | ARS | Filing |
| May 4, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2026 | 424B3 | Prospectus |
| Apr 29, 2026 | 10-K/A | [Amend] Annual report |
| Apr 27, 2026 | 424B3 | Prospectus |
| Apr 24, 2026 | 8-K | Current Report |
| Apr 23, 2026 | 424B3 | Prospectus |
| Apr 21, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | EFFECT | Notice of Effectiveness |